David Belada

6PUBLICATIONS
24CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCellular immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.

|Oct 01, 2024
Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data.

Heidi Mocikova, Andrea Janikova, Alice Sykorova

|Aug 09, 2024
Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy.

Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová

|Jun 27, 2023
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.

David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues

|Nov 28, 2022
A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia.

Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová

|Jul 18, 2022
Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP.

Vít Procházka, David Belada, Andrea Janíková

Pageof 1

Frequent Collaborators

2 joint publications

Martin Šimkovič

2 joint publications

Pavel Žák

2 joint publications

Doris Vokurková

2 joint publications

Lukáš Smolej